Mobile website
Archive > Volume 30 Issue 6 > 2023,30(6):455-463. DOI:10.3872/j.issn.1007-385X.2023.06.001 Prev Next
Expert Forum
Full-course management of therapy based on immune checkpoint inhibitors for advanced non-small cell lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Immunotherapy based on immune checkpoint inhibitor (ICI) has become the main treatment strategy for advanced non-small cell lung cancer (NSCLC)．By releasing immune checkpoint mediated immunosuppression, ICI restores the body's immune balance, improves the anti-tumor response rate, and significantly improves the prognosis of patients with advanced NSCLC. However, many problems remain unsolved in ICI treatment for advanced NSCLC. The present article will focus on the full-course management of ICI immunotherapy in advanced NSCLC patients, including prediction of immunotherapy efficacy, special patients screening before the initiation of ICI therapy, choice of the ICI drugs, development of new generation ICI drugs, restart of ICI immunotherapy after immune-related adverse event, ICI resistance, and the management of immune-related adverse events, in order to provide guidance for immunotherapy for advanced NSCLC patients.
Keywords:
Project Supported:
Clc Number:
